---
schema_version: "secwatch.filing_event.v1"
accession: "0001510964-22-000016"
form_type: "8-K"
ticker: "CVSI"
cik: "0001510964"
company_name: "CV Sciences, Inc."
filed_at: "2022-03-31T23:59:59+00:00"
generated_at: "2026-06-26T11:59:43.697114+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# CV Sciences reports FY2021 revenue down 18% to $20.0M; loss narrows to $18.4M

## Summary
- Revenue of $20.0M for FY2021, down 18% from $24.4M in 2020.
- Gross margin declined to 43.0% from 45.1%; cash fell to $1.4M from $4.5M.
- Operating loss improved to $18.4M from $22.6M; adjusted EBITDA negative $10.0M.
- Retail distribution expanded to 8,400+ stores from 7,300 as of Dec 31, 2021.
- Launched new products; GNC distribution agreement; PPP loan forgiveness of $2.9M.

## SEC filing metadata
- accession: 0001510964-22-000016
- form_type: 8-K
- ticker: CVSI
- cik: 0001510964
- company_name: CV Sciences, Inc.
- filed_at: 2022-03-31T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1510964/000151096422000016/0001510964-22-000016-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1510964/000151096422000016/cvsi-20220331.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001510964-22-000016
- JSON: https://secwatch.observer/filing/0001510964-22-000016.json
- Plain text: https://secwatch.observer/filing/0001510964-22-000016.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.